Biocryst Pharmaceuticals Inc (BCRX): Next-Year EPS Estimate 111.70%
As of 2026-06-11, Biocryst Pharmaceuticals Inc (BCRX) has a next-year EPS growth estimate of 111.70%.
On 2026-05-17, analyst consensus for BCRX's next-year EPS growth shifted from 112.68% to 111.70% — a negative change of 0.98 percentage points. The revised estimate has been sustained across 20 subsequent trading sessions. Current-year growth is projected at -321.28%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 111.70%
- EPS growth this year
- -321.28%
- EPS next quarter (est)
- $0.16
- Last price
- $8.50
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-11 | 111.70% | -321.28% | $0.16 | $8.50 |
| 2026-06-10 | 111.70% | -321.28% | $0.16 | $8.19 |
| 2026-06-09 | 111.70% | -321.28% | $0.16 | $8.33 |
| 2026-06-08 | 111.70% | -321.28% | $0.16 | $8.43 |
| 2026-06-07 | 111.70% | -321.28% | $0.16 | $8.41 |
| 2026-06-04 | 111.70% | -321.28% | $0.16 | $8.47 |
| 2026-06-03 | 111.70% | -321.28% | $0.16 | $8.25 |
| 2026-06-02 | 111.70% | -321.28% | $0.16 | $8.34 |
| 2026-06-01 | 111.70% | -321.28% | $0.16 | $8.57 |
| 2026-05-31 | 111.70% | -321.28% | $0.16 | $8.91 |
| 2026-05-28 | 111.70% | -321.28% | $0.16 | $9.10 |
| 2026-05-27 | 111.70% | -321.28% | $0.16 | $9.12 |
| 2026-05-26 | 111.70% | -321.28% | $0.16 | $8.47 |
| 2026-05-25 | 111.70% | -321.28% | $0.16 | $8.29 |
| 2026-05-24 | 111.70% | -321.28% | $0.16 | $8.29 |
| 2026-05-21 | 111.70% | -321.28% | $0.16 | $8.37 |
| 2026-05-20 | 111.70% | -321.28% | $0.16 | $8.74 |
| 2026-05-19 | 111.70% | -321.28% | $0.16 | $8.77 |
| 2026-05-18 | 111.70% | -321.28% | $0.16 | $8.97 |
| 2026-05-17 | 111.70% | -321.28% | $0.16 | $9.02 |
| 2026-05-14 | 112.68% | -325.97% | $0.13 | $9.57 |
| 2026-05-13 | 112.68% | -325.97% | $0.13 | $9.67 |
| 2026-05-12 | 112.68% | -325.97% | $0.13 | $8.80 |
| 2026-05-11 | 112.68% | -325.97% | $0.13 | $8.58 |
| 2026-05-10 | 112.68% | -325.97% | $0.13 | $8.62 |
| 2026-05-07 | 114.92% | -292.05% | $0.13 | $8.90 |
| 2026-05-06 | 182.25% | -137.97% | $0.09 | $8.83 |
| 2026-05-05 | 73.81% | -77.64% | $0.04 | $9.03 |
| 2026-05-04 | 73.81% | -77.64% | $0.04 | $9.20 |
| 2026-05-03 | 73.81% | -77.64% | $0.04 | $9.19 |
Screen Performance
Aggregate stats across all 1781 tickers our top-EPS-revision screen has flagged over the past 71 days.
- Median return since detection
- +3.8%
- % of tickers in the green
- 58%
- Median return on winners
- +18.5%
- Large revisions captured
- 788
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Biocryst Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-06-11, Biocryst Pharmaceuticals Inc (BCRX) has a next-year EPS growth estimate of 111.70%, based on analyst consensus.
When was the latest EPS estimate revision for BCRX?▾
The most recent revision occurred on 2026-05-17, when analysts adjusted the next-year EPS growth estimate from 112.68% to 111.70%.
What sector and industry does Biocryst Pharmaceuticals Inc belong to?▾
Biocryst Pharmaceuticals Inc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BCRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Biocryst Pharmaceuticals Inc (BCRX) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports